Chlorpromazine versus piperacetazine for schizophrenia

. 2018 Oct 31;2018(10):CD011709. doi: 10.1002/14651858.CD011709.pub2

Study	Reason for exclusion
Small 1970	Allocation: unknown. Participants: adults with acute and chronic schizophrenia, N = 29. Interventions: chlorpromazine (liquid form; minimum dose of 60 mg/day, maximum dose of 1200 mg/day) versus piperacetazine (liquid form; minimum dose of 20 mg/day, maximum dose of 160 mg/day). Outcomes: all data impossible to use ‐ Mental state: CGI, NOSIE (no mean or SD). Global state – BPRS (no mean or SD). Adverse effects (total numbers in each group not given). Leaving the study early (total numbers in each group not given).

Study

Reason for exclusion

Small 1970

Allocation: unknown.
Participants: adults with acute and chronic schizophrenia, N = 29.
Interventions: chlorpromazine (liquid form; minimum dose of 60 mg/day, maximum dose of 1200 mg/day) versus piperacetazine (liquid form; minimum dose of 20 mg/day, maximum dose of 160 mg/day).
Outcomes: all data impossible to use ‐
Mental state: CGI, NOSIE (no mean or SD).
Global state – BPRS (no mean or SD).
Adverse effects (total numbers in each group not given).
Leaving the study early (total numbers in each group not given).

BPRS ‐ Brief Psychiatric Rating Scale  CGI ‐ Clinical Global Impression  NOSIE ‐ Nurses' observation of Scale for Inpatient Evaluation  SD ‐ Standard Deviation